| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1572 | 2019 |
| Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ... The Lancet Oncology 20 (12), 1655-1669, 2019 | 519 | 2019 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 448 | 2021 |
| Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium … SJ Kim, K Kim, BS Kim, CY Kim, C Suh, J Huh, SW Lee, JS Kim, J Cho, ... | 400 | 2009 |
| A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis SJ Kim, DH Yoon, A Jaccard, WJ Chng, ST Lim, H Hong, Y Park, ... The lancet oncology 17 (3), 389-400, 2016 | 356 | 2016 |
| The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer MH Kang, SI Go, HN Song, A Lee, SH Kim, JH Kang, BK Jeong, KM Kang, ... British journal of cancer 111 (3), 452-460, 2014 | 245 | 2014 |
| A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia JH Lee, YD Joo, H Kim, SH Bae, MK Kim, DY Zang, JL Lee, GW Lee, ... Blood, The Journal of the American Society of Hematology 118 (14), 3832-3841, 2011 | 199 | 2011 |
| Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M–positive NSCLC following previous EGFR TKI therapy: CAURAL brief report JCH Yang, FA Shepherd, DW Kim, GW Lee, JS Lee, GC Chang, SS Lee, ... Journal of Thoracic Oncology 14 (5), 933-939, 2019 | 182 | 2019 |
| Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia DY Kim, YD Joo, SN Lim, SD Kim, JH Lee, JH Lee, DH Kim, K Kim, ... Blood, The Journal of the American Society of Hematology 126 (6), 746-756, 2015 | 175 | 2015 |
| Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement MK Song, JS Chung, HJ Shin, SM Lee, SE Lee, HS Lee, GW Lee, SJ Kim, ... Annals of hematology 91, 697-703, 2012 | 156 | 2012 |
| Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules IT Nizamutdinova, GW Lee, JS Lee, MK Cho, KH Son, SJ Jeon, SS Kang, ... Carcinogenesis 29 (10), 1885-1892, 2008 | 132 | 2008 |
| Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine JH Lee, YD Joo, H Kim, HM Ryoo, MK Kim, GW Lee, JH Lee, WS Lee, ... Journal of Clinical Oncology 31 (6), 701-709, 2013 | 131 | 2013 |
| Leptomeningeal carcinomatosis in gastric cancer JL Lee, YK Kang, TW Kim, HM Chang, GW Lee, MH Ryu, E Kim, SJ Oh, ... Journal of neuro-oncology 66, 167-174, 2004 | 130 | 2004 |
| Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open … MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim, YG Lee, EK Cho, JH Kim, ... The Lancet Oncology 20 (12), 1681-1690, 2019 | 127 | 2019 |
| Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells IT Nizamutdinova, GW Lee, KH Son, SJ Jeon, SS Kang, YS Kim, JH Lee, ... International journal of oncology 33 (3), 485-491, 2008 | 125 | 2008 |
| Human adipose tissue-derived mesenchymal stem cells protect kidneys from cisplatin nephrotoxicity in rats JH Kim, DJ Park, JC Yun, MH Jung, HD Yeo, HJ Kim, DW Kim, JI Yang, ... American Journal of Physiology-Renal Physiology 302 (9), F1141-F1150, 2012 | 112 | 2012 |
| Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer SI Go, MJ Park, HN Song, MH Kang, HJ Park, KN Jeon, SH Kim, MJ Kim, ... Supportive care in cancer 24, 2075-2084, 2016 | 108 | 2016 |
| Prognostic impact of sarcopenia in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone SI Go, MJ Park, HN Song, HG Kim, MH Kang, HR Lee, Y Kim, RB Kim, ... Journal of cachexia, sarcopenia and muscle 7 (5), 567-576, 2016 | 102 | 2016 |
| Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study SJ Lee, HR Lee, TW Lee, S Ju, S Lim, SI Go, JW You, YJ Cho, GW Lee, ... The Korean journal of internal medicine 31 (5), 891, 2016 | 90 | 2016 |
| Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma GW Lee, JH Kang, HG Kim, JS Lee, JS Lee, JS Jang American journal of clinical oncology 29 (2), 127-131, 2006 | 87 | 2006 |
